Enliven Therapeutics, Inc.
ELVN · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$120M | −$105M | −14.5% |
| Net income | −$104M | −$89.0M | −16.5% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$36.0M | −$25.1M | −43.4% |
| Net income | −$27.7M | −$20.1M | −37.8% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Enliven's revenue in FY2025?
- $0K in FY2025 (Fiscal year ended Dec 31, 2025), no comparable figure vs $0K a year earlier, per its 10-K filed Mar 2026.
- Was Enliven profitable in FY2025?
- No: net income was −$104M and operating income −$120M in FY2025.
- What was Enliven's revenue in Q3 2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Nov 5, 2026.